TrialAmerican journal of nephrology2025

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study.

Takayuki Hamano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.